Life sciences enterprises are evolving their commercial technology landscape to suit changing customer preferences and are shifting from a completely physical, representative-based sales model to a more stable hybrid commercial model. To unlock maximum value from the commercial technology and deliver a consistent and hyper-personalized Customer Experience (CX), the hybrid commercial model needs to integrate diverse datasets, achieve higher efficacy of data transformation, reduce insights generation time, and improve collaboration between all internal functions. Therefore, life sciences enterprises cannot sustain a hybrid commercial model solely by relying on historical data analysis (descriptive analytics) and IT-led Business Intelligence (BI). They need to invest in next-generation AI-enabled analytics and BI tools to meet the changing needs and preferences of evolved customers. However, most existing commercial analytics and BI tools/solutions are not adept at adapting to this evolving technology landscape.

In this report, we demonstrate the value of augmented analytics tools and BI platforms for the life sciences commercial function and shed light on their key use cases across the sales, marketing, and managed markets functions. Additionally, the report also provides suggestions on how life sciences firms can get started and build momentum to maximize the outcomes from their augmented analytics initiatives using Everest Group’s enterprise blueprint for success in scaling augmented analytics tools.

Scope

• Industry: life sciences
• Geography: global

Contents

In this report, we:

• Establish the business case for augmented analytics in the life sciences commercial function
• Examine the value that augmented analytics provide
• Enlist the augmented analytics use cases across prominent life sciences commercial functions
• Provide a roadmap for successfully adopting augmented analytics tools

Membership(s)

Life Sciences Information Technology

Sourcing and Vendor Management